S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
pixel
Log in
NASDAQ:LMAT

LeMaitre Vascular Stock Forecast, Price & News

$45.43
+0.66 (+1.47 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$44.28
Now: $45.43
$45.70
50-Day Range
$34.49
MA: $39.56
$44.91
52-Week Range
$18.76
Now: $45.43
$45.77
Volume65,681 shs
Average Volume97,441 shs
Market Capitalization$924.14 million
P/E Ratio48.85
Dividend Yield0.85%
Beta1.43
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. It also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, the company offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes, which cut valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, it provides vascular patches, which are used for closure of vessels after surgical intervention, as well as endarterectomy and other vascular reconstruction; vessel closure systems to attach vessels to one another with titanium clips instead of sutures; and surgical glue. The company markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was founded in 1983 and is headquartered in Burlington, Massachusetts.
LeMaitre Vascular logo

MarketRank

Overall MarketRank

1.87 out of 5 stars

Medical Sector

101st out of 1,923 stocks

Surgical & Medical Instruments Industry

12th out of 169 stocks

Analyst Opinion: 1.3Community Rank: 2.9Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LMAT
CUSIPN/A
Phone781-221-2266
Employees454

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$117.23 million
Cash Flow$1.28 per share
Book Value$7.41 per share

Profitability

Net Income$17.93 million

Miscellaneous

Market Cap$924.14 million
Next Earnings Date2/4/2021 (Estimated)
OptionableOptionable
$45.43
+0.66 (+1.47 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LMAT News and Ratings via Email

Sign-up to receive the latest news and ratings for LMAT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











LeMaitre Vascular (NASDAQ:LMAT) Frequently Asked Questions

How has LeMaitre Vascular's stock price been impacted by Coronavirus?

LeMaitre Vascular's stock was trading at $26.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, LMAT shares have increased by 74.1% and is now trading at $45.43.
View which stocks have been most impacted by COVID-19
.

Is LeMaitre Vascular a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LeMaitre Vascular in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LeMaitre Vascular stock.
View analyst ratings for LeMaitre Vascular
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than LeMaitre Vascular?

Wall Street analysts have given LeMaitre Vascular a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but LeMaitre Vascular wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is George W. LeMaitre's approval rating as LeMaitre Vascular's CEO?

13 employees have rated LeMaitre Vascular CEO George W. LeMaitre on Glassdoor.com. George W. LeMaitre has an approval rating of 33% among LeMaitre Vascular's employees. This puts George W. LeMaitre in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is LeMaitre Vascular's next earnings date?

LeMaitre Vascular is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for LeMaitre Vascular
.

How were LeMaitre Vascular's earnings last quarter?

LeMaitre Vascular, Inc. (NASDAQ:LMAT) released its earnings results on Thursday, October, 29th. The medical instruments supplier reported $0.37 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.19 by $0.18. The medical instruments supplier had revenue of $36.42 million for the quarter, compared to the consensus estimate of $31.62 million. LeMaitre Vascular had a net margin of 15.41% and a trailing twelve-month return on equity of 12.32%. The business's quarterly revenue was up 25.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.25 earnings per share.
View LeMaitre Vascular's earnings history
.

How often does LeMaitre Vascular pay dividends? What is the dividend yield for LeMaitre Vascular?

LeMaitre Vascular announced a quarterly dividend on Monday, November 2nd. Stockholders of record on Thursday, November 19th will be paid a dividend of $0.095 per share on Thursday, December 3rd. This represents a $0.38 dividend on an annualized basis and a dividend yield of 0.84%. The ex-dividend date is Wednesday, November 18th.
View LeMaitre Vascular's dividend history
.

Is LeMaitre Vascular a good dividend stock?

LeMaitre Vascular pays an annual dividend of $0.38 per share and currently has a dividend yield of 0.85%. The dividend payout ratio of LeMaitre Vascular is 43.18%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LeMaitre Vascular will have a dividend payout ratio of 32.20% next year. This indicates that LeMaitre Vascular will be able to sustain or increase its dividend.
View LeMaitre Vascular's dividend history.

What guidance has LeMaitre Vascular issued on next quarter's earnings?

LeMaitre Vascular issued an update on its fourth quarter earnings guidance on Thursday, October, 29th. The company provided EPS guidance of $0.25 to $0.35 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.21. The company issued revenue guidance of $34 million to $38 million, compared to the consensus revenue estimate of $33.46 million.

What price target have analysts set for LMAT?

6 analysts have issued 1 year target prices for LeMaitre Vascular's stock. Their forecasts range from $30.00 to $46.00. On average, they anticipate LeMaitre Vascular's stock price to reach $35.67 in the next year. This suggests that the stock has a possible downside of 21.5%.
View analysts' price targets for LeMaitre Vascular
or view Wall Street analyst' top-rated stocks.

Who are some of LeMaitre Vascular's key competitors?

What other stocks do shareholders of LeMaitre Vascular own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LeMaitre Vascular investors own include (CGC), AbbVie (ABBV), Sociedad Química y Minera de Chile (SQM), Gilead Sciences (GILD), Aurora Cannabis (ACB), Aurora Cannabis (ACBFF), NVIDIA (NVDA), Adobe (ADBE), The Boeing (BA) and salesforce.com (CRM).

Who are LeMaitre Vascular's key executives?

LeMaitre Vascular's management team includes the following people:
  • Mr. George W. LeMaitre, Chairman & CEO (Age 56, Pay $678.25k)
  • Mr. David B. Roberts, Pres & Director (Age 57, Pay $498.87k)
  • Mr. Joseph P. Pellegrino Jr., CFO, Treasurer, Sec. & Director (Age 56, Pay $438.02k)
  • Mr. Trent G. Kamke, Sr. VP of Operations (Age 50, Pay $357.85k)
  • Dr. George D. LeMaitre, Founder and Chairman of Scientific Advisory Board (Age 87)
  • Ms. Laurie A. Churchill, Sr. VP & Gen. Counsel (Age 50)
  • Ms. Kimberly L. Cieslak, VP of Marketing (Age 48)
  • Mr. Andrew Hodgkinson, Sr. VP of Clinical, Regulatory & Quality Affairs (Age 45)

What is LeMaitre Vascular's stock symbol?

LeMaitre Vascular trades on the NASDAQ under the ticker symbol "LMAT."

Who are LeMaitre Vascular's major shareholders?

LeMaitre Vascular's stock is owned by many different retail and institutional investors. Top institutional investors include Summit Creek Advisors LLC (2.25%), State of Alaska Department of Revenue (0.06%), Avantax Advisory Services Inc. (0.03%) and Crossmark Global Holdings Inc. (0.03%). Company insiders that own LeMaitre Vascular stock include David B Roberts, George W Lemaitre, John A Roush, Joseph P Pellegrino Jr, Lawrence J Jasinski, Michael H Thomas and Trent G Kamke.
View institutional ownership trends for LeMaitre Vascular
.

Which major investors are selling LeMaitre Vascular stock?

LMAT stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, and State of Alaska Department of Revenue. Company insiders that have sold LeMaitre Vascular company stock in the last year include George W Lemaitre, John A Roush, Joseph P Pellegrino Jr, Lawrence J Jasinski, and Trent G Kamke.
View insider buying and selling activity for LeMaitre Vascular
or view top insider-selling stocks.

Which major investors are buying LeMaitre Vascular stock?

LMAT stock was bought by a variety of institutional investors in the last quarter, including Avantax Advisory Services Inc., and Crossmark Global Holdings Inc..
View insider buying and selling activity for LeMaitre Vascular
or or view top insider-buying stocks.

How do I buy shares of LeMaitre Vascular?

Shares of LMAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is LeMaitre Vascular's stock price today?

One share of LMAT stock can currently be purchased for approximately $45.43.

How big of a company is LeMaitre Vascular?

LeMaitre Vascular has a market capitalization of $924.14 million and generates $117.23 million in revenue each year. The medical instruments supplier earns $17.93 million in net income (profit) each year or $0.88 on an earnings per share basis. LeMaitre Vascular employs 454 workers across the globe.

What is LeMaitre Vascular's official website?

The official website for LeMaitre Vascular is www.lemaitre.com.

How can I contact LeMaitre Vascular?

LeMaitre Vascular's mailing address is 63 SECOND AVENUE, BURLINGTON MA, 01803. The medical instruments supplier can be reached via phone at 781-221-2266.

This page was last updated on 1/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.